Tharimmune, INC

Canton Strategic Holdings, Inc. announced its second quarter 2026 financial results, marking the first operating revenue from its locking service and Super Validator operations, alongside the sale of its legacy biotechnology subsidiary.

Canton Strategic Holdings, Inc. has sold its wholly owned subsidiary, Gravitas Life Sciences, LLC, to Gravitas Collective Corp. for a $3.5 million promissory note and potential milestone payments.

Canton Strategic Holdings, Inc. announced the results of its 2026 annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

Canton Strategic Holdings announced its Board of Directors has authorized a $50 million share repurchase program, signaling confidence in its platform and long-term value.

Canton Strategic Holdings announced full year 2025 financial and operational results, highlighting its new digital asset strategy and strengthened capital position.

Canton Strategic Holdings' Chairman and CEO, Mark Wendland, has been elected to the Board of Directors of the Canton Foundation, reinforcing the company's role in digitizing financial markets.

Canton Strategic Holdings, Inc. reported its second quarter 2026 financial results, highlighting new revenue from network validation and locking-as-a-service, but also significant unrealized losses on its digital asset holdings.

Canton Strategic Holdings reports a significant increase in net loss for Q1 2026, primarily driven by its digital asset strategy and substantial unrealized losses on its Canton Coin holdings.

Tharimmune, a clinical-stage biotech, reported a reduced net loss in Q3 2025 and secured over $545 million in new capital, including a significant cryptocurrency offering, while also announcing major leadership changes and a new digital asset treasury strategy.

Tharimmune, a clinical-stage biotech, reported continued operating losses and a going concern warning, despite progress in its drug pipeline and recent capital raises, alongside significant management changes.

Tharimmune, a clinical-stage biotechnology company, announced its Q1 2025 financial results, highlighting a net loss of $2.54 million and a strategic shift towards prioritizing its TH104 program for opioid prophylaxis.

Tharimmune Inc. reported a net loss of $3.8 million for the third quarter of 2024, alongside updates on clinical trials and strategic agreements.

Canton Strategic Holdings, Inc. has completed a major strategic shift from biotechnology to a digital asset treasury strategy focused on Canton Coin and the Canton Network, raising over $537 million in capital.

Tharimmune, Inc. releases its 2024 annual report, detailing clinical advancements and financial results, while acknowledging substantial doubt about its ability to continue as a going concern.

Tharimmune, Inc., a clinical-stage biotechnology company, released its 2023 annual report, highlighting progress in its pipeline and financial position.

Director Gary Stetz of Canton Strategic Holdings, Inc. reported the sale of 100,351 shares of common stock across multiple transactions in May 2026.

Tharimmune's Chief Operating Officer, Sanam Parikh, acquired 5,000 stock options exercisable at $3.075 per share, increasing total beneficial ownership to 55,000 options.

Tharimmune Director James Gordon Liddy acquired 5,000 stock options with an exercise price of $3.075, increasing his total beneficial ownership of derivative securities to 55,000.

Tharimmune's Executive Chairman, Vincent S LoPriore, was granted 90,000 stock options with an exercise price of $3.075, effective November 3, 2025.

Tharimmune, Inc. Director Nancy Davis Rickel acquired 5,000 stock options at an exercise price of $3.075.

Tharimmune, Inc. Director Gary S. Stetz acquired 32,500 stock options with an exercise price of $3.075, bringing his total beneficial ownership to 82,500 options.

Canton Strategic Holdings, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on July 13, 2026.

Tharimmune, Inc. issued a supplement to its proxy statement clarifying the independent status of two director nominees for its upcoming Special Meeting of Stockholders.

Tharimmune, Inc. calls a special meeting to vote on new directors, significant equity issuances for strategic advisors and private placements, and an expansion of its equity incentive plan.

Tharimmune, Inc. calls a special meeting to vote on increasing authorized common stock, expanding its equity incentive plan, and authorizing future non-public offerings to support growth and capital needs.

Tharimmune Inc. issues a supplement to its proxy statement to correct an error related to the reported beneficial ownership of shares by Vincent LoPriore.

Tharimmune, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Gravitas Capital LP and its managing member, Vincent S. LoPriore, who also serves as Tharimmune, Inc.'s Executive Chairman, have disclosed a combined beneficial ownership of 14.83% of the company's Common Stock, acquired for investment purposes.

ARK Investment Management LLC and Catherine D. Wood have jointly filed a Schedule 13G, reporting beneficial ownership of 4.74% of Canton Strategic Holdings, Inc. common stock as of June 30, 2026.

A group of investors led by Murtaza S. Akbar and Emil Woods disclosed a 9.99% beneficial ownership stake in Canton Strategic Holdings, Inc. via a Schedule 13G filing.

Broadridge Financial Solutions, Inc. has reported a 9.99% beneficial ownership stake in THARIMMUNE, INC., primarily through warrants.

ARK Investment Management LLC and Catherine D. Wood have jointly disclosed a beneficial ownership of 8.92% in Tharimmune, Inc. common stock.

LCV Funds and related entities have reported a beneficial ownership of approximately 9.99% in Tharimmune, Inc., primarily through common stock and exercisable warrants.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 2.2% of THARIMMUNE INC's common stock as of December 31, 2025.